Skip to content

Trial · Interventional

Active, not recruitingPhase 3Registry data

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

NCTNCT06948422 (opens ClinicalTrials.gov in a new tab)Other id27223Other idJ2A-MC-GZPLOther idJ2A-MC-GZL1Other idJ2A-MC-GZL2
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Active, not recruiting
Phase
Phase 3
Enrollment
974 participants (estimated)
Sponsor
Eli Lilly and Company · Industry
Design
Randomized · Double masking
Countries
11 countries

United States, Argentina, China, Czechia, Germany, Greece, India, Japan, Poland, Puerto Rico, Spain

Start
30 Apr 2025
Primary completion
Sept 2027 (estimated)
Completion
Sept 2027 (estimated)
First posted
29 Apr 2025
Last update posted
29 May 2026
Conditions
Hypertension

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2025202620272028
  1. Ph 3

    A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

    NCT06948422

    30 Apr 2025 to est. Sept 2027

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a framework to evaluate the safety and efficacy of orforglipron for the treatment of hypertension in participants with obesity or overweight.

Interventions

  • OrforglipronDrug
  • PlaceboDrug

Arms2

  • Experimental

    Orforglipron (GZL1)

    Participants will receive orforglipron orally or placebo.

  • Experimental

    Orforglipron (GZL2)

    Participants will receive orforglipron orally or placebo.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Number of Participants Allocated to Each ISA

    Time frame · Week -8 to Week 0

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

0 studies on this page

PubMed tag: none · 2026

Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension.

Laffin et al. 2026American journal of preventive cardiology

PMID 42830762PMC13633904DOI 10.1016/j.ajpc.2026.101783PUB-42830762

CC BY
Download PDF

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Has systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg (if DBP criteria alone is met, SBP must be ≥130 mmHg) at screening (Visit 1). * Has SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg (if DBP criteria alone is met, SBP must be ≥130 mmHg) at week 0 (Visit 3). * Untreated for hypertension, or on stable antihypertensive medications ≥ 30 days prior to Visit 1. * Have a body mass index (BMI) ≥ 25 kg/m². Exclusion Criteria: * Has SBP ≥170 mmHg and/or DBP ≥110 mmHg at Visit 1 or at Visit 3. * Has known secondary causes of hypertension * Have heart failure with reduced ejection fraction (HFrEF) diagnosis * Have had any of the following conditions within 90 days prior to screening. * hospitalization for hypertension or for congestive heart failure * acute coronary syndrome or acute myocardial infarction, or * cerebrovascular accident (stroke). * Have type 1 diabetes (T1D) * Have acute or chronic hepatitis, including a history of autoimmune hepatitis

PepBank is a research reference. Talk to a doctor before you use any peptide.